VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

por Nadiminti, Kalyan, Singh Abbi, Kamal Kant, Mott, Sarah L, Dozeman, Lindsay, Tricot, Annick, Schultz, Allyson, Behrends, Sonya, Zhan, Fenghuang, Tricot, Guido
Publicado 2017

A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction

por Nadiminti, Kalyan, Langer, Kimberly, Shabbir, Ehsan, Hefazi, Mehrdad, Dozeman, Lindsay, Jethava, Yogesh, Loeffler, Bradley, AlKhateeb, Hassan B., Litzow, Mark, Patnaik, Mrinal, Shah, Mithun, Hogan, William, Farooq, Umar, Silverman, Margarida, Mott, Sarah L.
Publicado 2021